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Background
The blood supply today is safer than ever, mainly due to more 
careful donor selection and, in developed countries, the use of 
nucleic acid amplification testing (NAT) for transfusion-trans-
mitted diseases (TTDs) such as HBV, HCV, HIV and syphilis. A 
highly effective donor selection program including a confiden-
tial unit exclusion (CUE) option and donor medical histories has 
special importance in developing countries such as Iran, where 
NAT has not been implemented and approximately 60% of par-
ticipants are first-time donors, for whom the prevalence of posi-
tive serological tests for TTDs is higher than in repeat donors (1). 
In the United States, the use of CUE was recommended by the 
US Food and Drug Administration in 1986 (2). CUE gives a donor 
the opportunity to indicate in confidence that the donated unit 
should not be used for transfusion. Donors who choose CUE may 
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know or suspect that they have risk factors, and may donate so 
as to obtain test results for infections such as HBV, HCV and HIV. 
A number of studies have examined CUE effectiveness. Pindy-
ck et al. found significant differences in the prevalence of posi-
tive laboratory tests in donors excluding themselves compared 
to donors who did not exclude themselves (3). A separate study 
reported that donors who excluded themselves were more 
likely to be HIV Ab positive than donors who did not exclude 
themselves. However, infrequency of confidential exclusion by 
window-period donors causes the CUE option to have minimal 
impact on blood safety (4). In another study, low sensitivity and 
low positive predictive value was seen in a CUE implementation 
(5). CUE has been used at the Tehran Blood Transfusion Center 
(TBTC) since 2003. However, no study has examined CUE effec-
tiveness in Iran.12
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Objectives
This study evaluated the efficacy of CUE for blood safety by 
comparing the prevalence of TTD markers in CUE users and non-
CUE users at TBTC.
Patients and Methods
Our analysis is based upon a database representing all dona-
tions at TBTC. TBTC receives voluntary blood from 25 collection 
centers across the city. Each center uses a standardized blood 
donor record. This record contains demographic information, 
donor status (first-time or repeat), medical history, physical 
examination, CUE designation, blood group, TTD markers, and 
confirmatory testing results for positive donations. This infor-
mation for each donation is added to the TBTC database.In the 
Iranian Blood Transfusion Organization (IBTO), in order to en-
sure blood safety, all donors must undergo a complete medical 
history and fill out the CUE form. Each donor’s medical history 
is reviewed by a qualified physician through a questionnaire 
and a personal interview. The vast majority of items in the ques-
tionnaire are intended to determine if the donor has risk factors 
for exposure to an increasing number of proven or potential 
TTDs. The physician rejects those donors with any risk factors 
for TTDs, such as intravenous drug abuse, history of blood trans-
fusion, tattoo, acupuncture, body piercing, surgery, allogeneic 
and syngeneic transplantation, tooth extraction, liver disease, 
jaundice, lymphadenopathy, in addition to those with positive 
serologic markers for TTDs.
After undergoing a medical history, the CUE form is given to 
the donor. This form contains information about TTDs and has 
two options, as follows:
•“My blood can be used for patients.”
•“My blood should not be used for patients.”
The donor must choose one of the two options by ticking a 
check mark and then place this form into the certain box in the 
center. If the donor chooses the should-not-be-used option (CUE 
positive), the unit and all products from that unit will be de-
stroyed, regardless of its test results.In this study, data from vol-
untary first-time and repeat donations in 2006 were analyzed. 
The data were divided into two groups: CUE positive and CUE 
negative. As the population of CUE-negative donations was very 
large compared to the population of CUE-positive donations, a 
random sample of CUE-negative donations that was four times 
the size of the CUE-positive population was taken. Descriptive 
statistics were calculated for both groups. The prevalence rates 
of HBV, HCV, HIV and syphilis markers among first-time and 
repeat donors in both groups were then calculated. For each 
marker, the prevalence was calculated as the number of con-
firmed-positive donations divided by the total number of dona-
tions (6). The following screening tests for TTDs were used: HBs 
Ag (Enzygnost HBs Ag 5.0, Dade Behring), anti-HCV (Hepanos-
tika microelisa system, bioMérieux, Marcy l'Etoile, France), HIV 
Ag/Ab (Vironostika, HIV Uni-Form II Ag/Ab microelisa system, 
bioMérieux) and RPR (Enison, RPR slide test). Confirmatory tests 
were performed on all repeatedly reactive donations using the 
following tests: HBs Ag (HBs Ag Confirmatory Assay, Dade Beh-
ring), anti-HCV (HCV RIBA 3.0, Genelabs Diagnostics), Anti-HIV 
(HIV BLOT 2.2, Genelabs Diagnostics) and RPR (FTA-ABS Test Sys-
tem, Mardx Diagnostics). A first-time donor was defined as an 
individual who never donated before; a lapsed donor was de-
fined as an individual whose previous donation was more than 1 
year ago; and a repeat donor was defined as an individual whose 
previous donation was less than 1 year ago. Repeat donors with 
CUE were those who used the CUE option in their last donation 
attempt. 
Statistical analysis
Statistical analysis was carried out using SPSS 16 software and 
comparisons were evaluated with chi-square test. A p<0.05 and 
a 95% confidence interval (CI) of odds ratio that does not contain 
1 was considered significant.
Results
Descriptive analyses in CUE-positive versus CUE-nega-
tive donors 
There were 2,864 (0.92%) CUE-positive and 307,782 (99.08%) 
CUE-negative donations. In order to compare these two groups, 
11,456 CUE-negative donations were chosen randomly. Table 1 
Table 1. Descriptive statistics of CUE-positive and CUE-negative donors in 2006
CUE
Number 
of 
donation
          11456               10660 (93)                        796 (7)                             6093 (53.1)                              4297 (37.5)                    1066 (9.3)
Positive        2864                                  2776 (97)                     88 (3)                         1999 (69.8)                              658 (23)                 207 (7.2)
Negative
Male 
(% population 
subset)
Female 
(% population 
subset)
First time
(% population 
subset)
Repeat 
(% population 
subset)
Lapsed 
(% population 
subset)
Table 2. Prevalence of TTD markers in CUE-positive versus CUE-negative donors in 2006
Marker                CUE               Total number  Number positive               Prevalence (%)                 p-value    Odds ratio(95% CI)
                        of donations                      for marker
 
HBs Ag                Negative               11456    54              0.5                    <0.0001     7.5 (5.4-10.5)
                Positive               2864    99              3.4       
HIV                Negative               11456    0              0                    0.3     3.9 (0.2-64)
                Positive               2864    0              0     
HCV                Negative               11456    12              0.1                    <0.0001     5.3 (2.5-11.3)
                Positive               2864    16              0.5     
Syphilis                Negative               11456    0              0                    0.3      3.9 (0.2-64)
                Positive               2864    0              0     
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shows descriptive statistics for CUE-positive and CUE-negative 
donors. In both groups, the majority were first-time donors 
and the large majority were male. Although the number of the 
first-time donors was higher than repeat donors in both groups, 
there was a significant relationship between first-time dona-
tion and being CUE positive (p<0.0001, odds ratio: 2.14, 95% CI: 
1.94-2.35). There was also a significant correlation between male 
gender and CUE-positive donations ( p<0.0001, odds ratio: 2.35, 
95% CI: 1.9-3).
Prevalence of TTD markers in CUE-positive versus CUE-
negative donors
Table 2 compares the prevalence rates of TTD markers be-
tween CUE-positive and CUE-negative donations. The prevalence 
of confirmed HBs Ag was 3.4% (99/2,864) among CUE-positive 
donations and 0.5% (54/11,456) among CUE-negative donations 
(p<0.0001, odds ratio: 7.5, 95% CI: 5.4-10.5). The prevalence of 
confirmed anti-HCV was 0.5% (54/11,456) among CUE-positive 
donations and 0.1% (12/11,456) among CUE-negative donations 
(p<0.0001, odds ratio: 5.3, 95% CI: 2.5-11.3). No anti-HIV or syphilis 
was detected.
Discussion
This study assessed the usefulness of CUE by comparing 
the prevalence rates of TTD markers in CUE-positive and CUE-
negative donations. Our data showed that the prevalence rate 
of HBV and HCV was significantly higher among CUE-positive 
donors than among CUE-negative donors. However, due to the 
low prevalence of HIV (0.1%) and syphilis in the general popu-
lation in Iran (7), a difference in risk with CUE status for these 
markers could not be demonstrated. Our results are consistent 
with a number of other studies. Brennan et al. showed that CUE 
was a useful adjunct to routine donor selection and minimized 
TTDs (8). Peterson found that CUE-positive donors were 21 times 
more likely to have HIV Ab, though the impact on blood safety 
was negligible due to the rarity of window-period donors (4). 
Zou et al. showed that CUE was effective for reducing the win-
dow period of TTDs, though not as effective as HCV and HIV NAT 
(9). Based on an analysis of TTD residual risk, the authors esti-
mated that CUE prevented the collection of 0.2 to 1.3 window-
period units. The authors suggested that, before NAT, CUE might 
have prevented the transfusion of a limited number of infected 
units(9). In contrast, in a retrospective and observational study, 
Cruze found little usefulness of CUE in avoiding major TTDs (10).
As NAT is currently unaffordable in Iran, CUE helps to improve 
blood transfusion safety. The prevalence rates of HBV, HCV and 
HIV in the general population in Iran have been estimated at 
3%, <1% and 0.1%, respectively (7, 11). However, with donor selec-
tion programs including CUE and laboratory screening, the cor-
responding rates in donated blood are 0.41%, 0.12% and 0.004% 
(12).There are few studies that have evaluated high-risk groups 
in Iran. HBV, HCV and HIV have similar modes of transmission 
and are relatively frequent among certain high-risk groups. Va-
hid found that close contact with an HBV-infected person, extra-
marital sexual contact and history of sexually transmitted dis-
ease were predictors of HBV infection in Iranian blood donors 
(13). Alavian et al. showed that intravenous drug abuse is the ma-
jor risk factor for HCV infection in Iranian blood donors, while 
sexual promiscuity, defined as one or more extramarital sexual 
relationships, is also associated with an increased risk of HCV in 
donors (14). From these reports, it is apparent that extramarital 
sexual contact and intravenous drug abuse are important risk 
factors for HBV, HCV and HIV infection in Iran. Males made up the 
large majority of donors in our study, and we found a significant 
association between male gender and CUE positivity. As males 
may have extramarital activity and unsafe sexual contact, male 
donors more often have undisclosed risk factors than females.
We also found that the majority of first-time donors were CUE 
positive. This high prevalence suggests that high-risk individu-
als use donation to find out whether they are infected. Based on 
the results of this study, as CUE-positive donors might have had 
higher rates of deferral risk, CUE is a useful tool for improving 
blood safety in the absence of HCV and HIV NAT.
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